Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. (Q37140318)
Jump to navigation
Jump to search
scientific article published on 19 January 2009
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. |
scientific article published on 19 January 2009 |
Statements
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205 (English)
T Li
P J Christos
J A Sparano
D L Hershman
S Hoschander
J J Wright
19 January 2009
1 reference
1 reference